Adalimumab Studied for Juvenile Rheumatoid Arthritis

Research is underway to evaluate the potential of the first fully human monoclonal antibody, D2E7 (adalimumab), in the treatment of juvenile rheumatoid arthritis and Crohn's disease.

Monoclonal antibodies mimic naturally occurring antibodies and can recognize and neutralize proteins that are linked to promoting the inflammatory process associated with many autoimmune diseases. Fully human monoclonal antibodies have a protein structure that makes them indistinguishable from antibodies found in the human body.

Juvenile rheumatoid arthritis and Crohn's disease are autoimmune diseases in which a human protein, tumor necrosis factor-alpha (TNF-alpha), has been shown to cause abnormal immune responses. D2E7 works by specifically targeting and blocking the activity of TNF-alpha.

"These new trials are enrolling patients who may be facing joint destruction at a young age with juvenile rheumatoid arthritis, or the serious gastrointestinal symptoms associated with Crohn's disease," said Dr. Charles J. Fisher, Jr., divisional vice president, Global Pharmaceutical Development at Abbott Laboratories.

The randomized, multi-center, double-blind Phase III trial will study the safety and effectiveness of D2E7 in patients with polyarticular juvenile arthritis.

"We've seen tremendous advances in the treatment of adult rheumatoid arthritis and studies in pediatric patients are critical to understanding the potential use of new treatments in children who are fighting destructive symptoms at a much younger age," said Dr. Daniel Lovell, chairman, Pediatric Rheumatology Study Group.

"This disease can be particularly troubling for children because of its impact on their ability to participate in activities with other children. The symptoms of juvenile rheumatoid arthritis are similar to adult rheumatoid arthritis, including swollen and tender joints that if untreated may affect a child's growth and development and lead to permanent joint destruction," Lovell said.

D2E7 is currently under review by the U.S. Food and Drug Administration for the treatment of adult rheumatoid arthritis.

Other sources: Abbott Laboratories